CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. - Wikidata - wikimedia - TriplyDB

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

http://www.wikidata.org/entity/Q30573747

about

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Acquired and intrinsic resistance in cancer immunotherapy Pathways and therapeutic targets in melanoma 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity Tumor infiltrating lymphocytes in ovarian cancer CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response.Current advances in T-cell-based cancer immunotherapy Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Advances and prospects in adoptive cell transfer therapy for ovarian cancer Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.CD137 is a Useful Marker for Identifying CD4+ T Cell Responses to Mycobacterium tuberculosis.Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.Triggering co-stimulation directly in melanoma tumor fragments drives CD8(+) tumor-infiltrating lymphocyte expansion with improved effector-memory properties.Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients.Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.Immuno-oncology combinations: raising the tail of the survival curve.Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation.Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis.CD137-CRDI is not necessary in the role of contacting its natural ligand.S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.Anticalin® Proteins as Therapeutic Agents in Human Diseases.Bispecific antibodies in cancer immunotherapy Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

P2860

Q26780387-E0CF3C62-9FFA-458D-8BCD-FDE93DDC4FF1 Q26827701-583E6639-AB22-4E4E-9A39-5BB4131F7128 Q26865736-0A79C1C1-146E-4601-BBCE-37FA98F51AAE Q27012963-D4BCB523-395D-4CCA-89CE-8F035E70715B Q27021878-AF2EE996-B2C4-444E-9841-5694AA81E6E0 Q28072933-1C25B882-FFB2-4E90-ABE0-1334C1DCC44D Q34550012-FDC81BE4-4B5A-4DF7-BE71-F681CE40B855 Q34781308-ADA7C6CE-703D-46E2-91F1-07A491E9FBE5 Q35215158-5E1FFD66-21B0-44AF-BBA0-0020D81D67F0 Q35677962-C1E0B28E-2BF0-41AB-8B09-CC64E21D2FBF Q36356392-A505CDE1-ACE1-4A4D-889F-7FE09BFAC5F5 Q36852332-ECF6F961-D391-4D48-B47C-263374DA2C0B Q37320131-B64B6678-2857-4ED0-84FB-8AE7EA4A8416 Q37489634-4BF99099-1222-4FBB-92FF-9890D5890D47 Q37688907-FE22F975-5638-4999-A1C8-93E9D0339233 Q37726682-6C566D9A-E8A8-4268-8505-6A4E667D8430 Q38223594-BEC9C6EF-84A2-4C52-8CA8-818CDBFFAC38 Q38636573-1C348597-F10A-48CA-AECE-94F9D7EF4503 Q38665128-7FD8472A-8D52-4399-8ACC-34F8F3A765F3 Q38784018-47E9824C-CAE7-4DD8-BE6E-D2E45F1F9DAB Q40325377-74D5CDC4-41F9-4419-9CC4-B9E81B2F8718 Q40774020-A5778521-AD45-4A67-8DFF-74F978DA6212 Q41807501-F2642684-B431-4B0E-A21F-A3033404C18C Q41911091-7AB88095-E3C3-4941-9535-96E5987425A9 Q41915705-F81B4AD4-B6FC-4C58-ABDD-FB280075C005 Q42078847-522E52E1-3E9F-4ADC-97DA-50DED4C9F840 Q42421273-E054A697-D4D3-4A15-855F-27450B6F150E Q42654278-F8ED01F1-1ADF-49B7-866C-BB4707C672BC Q42695489-C62157F5-64B4-416B-AC51-2924671999E6 Q43129884-05A3BA35-A986-4D5D-AD52-FA14877DA8D7 Q46047154-1346710F-D8E8-43E4-97B6-E7380D2364EA Q47335259-39D494BF-F3A7-43EA-8AD3-EFFD7EE63F99 Q47950137-F085F62B-B710-4FB7-ABA4-88E9D7487BD9 Q49185666-96598DA7-39E0-41EB-8A7E-ABE8F0C95643 Q50783362-62A8B87E-1DBD-43A6-97F6-C65523E80BBB Q52597566-5A3D2C12-65E8-430B-8E9F-00FEC731B7FB Q55484632-ADBF4EEE-22FF-4C7C-B78E-A55A3C7C673D Q56893015-5B9117DB-0064-4003-8C3C-116AE4EF50C9 Q57038247-0EB1F1BA-5ADF-4BE3-8220-CEEAF4941B98 Q57176182-39AFB7CC-ABF8-4B64-B47C-6E85241E0C7E

P2860

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.

http://www.wikidata.org/entity/Q30573747

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@ast

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@en

type

label

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@ast

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@en

prefLabel

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@ast

CD137 accurately identifies an ...... mor-reactive T cells in tumor.

@en

P1433

Q30573747-254D894B-FAD7-4A9F-95C3-307CCDDE1FA4

P1476

Q30573747-97ADB37B-E17F-4F40-87E3-76943C957894

P2093

Q30573747-38EFC412-265B-4EB2-B9AF-6220C5B4ABA9

Q30573747-59D206EA-16F7-4885-968C-9BE996549969

Q30573747-61B9A950-73AD-4657-BB7F-FF679FF533DF

Q30573747-9EC34BE9-D567-4C34-B2CD-5741F6B833C4

Q30573747-B3A2FC7C-9E40-4250-B153-A9BE52643A63

Q30573747-C8533BD1-7296-4920-A42D-7E1ECEA3D812

Q30573747-F7DC90CD-6ED4-4C02-8D80-F390B129E9B4

P2860

Q30573747-01FB2FB5-A1AF-42B5-99F1-40020A09ABE5

Q30573747-091C5B93-ED15-4EA1-8169-333AA9AF9FAC

Q30573747-0EA02413-889D-4F26-9C8A-DD7C8A949856

Q30573747-13823AA3-1B41-49D6-A480-9DE08C10E837

Q30573747-150955D8-1E05-498E-96F1-F86E26903E03

Q30573747-2813D1FE-D7E7-468D-9029-B115D4569D46

Q30573747-289AA190-7303-47CD-80C0-1013A0E3B862

Q30573747-28B1B664-1D98-4945-8D5C-981AA377E05B

Q30573747-2E01BD23-2E5F-464C-91B0-85878341488A

Q30573747-40035894-18F6-41BC-9595-ED040F0441F0

P304

Q30573747-1010E0CF-5F33-40C0-BA51-3FFEF6C943CE

P31

Q30573747-F3230958-0DD5-4F6E-BC46-6AB2F80EEF4B

P356

Q30573747-02C367A4-BF5F-4CC3-BD60-CED8CD67FF40

P407

Q30573747-E609FFFD-CCAD-4851-94C3-1A357E9305BE

P433

Q30573747-BB687744-5D32-4602-8700-14AD3DC9D4EF

P478

Q30573747-ECBF159F-826C-41E1-B16E-28F7874E88FB

P50

Q30573747-909C4606-AF7B-4D94-AAEF-BEC65D92E981

P577

Q30573747-98F207CC-626A-42D2-86F1-6CE84A785726

P698

Q30573747-BE61C9A4-0052-463A-9C6E-BB6A81298F87

P932

Q30573747-210D3022-96BF-46CD-9693-3C64885C80ED

P356

1078-0432.CCR-13-0945

P1433

Clinical Cancer Research

P1476

CD137 accurately identifies an ...... umor-reactive T cells in tumor

@en

P2093

Andrew Best

http://www.w3.org/2001/XMLSchema#string

Chunsheng Li

http://www.w3.org/2001/XMLSchema#string

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

De-Gang Song

http://www.w3.org/2001/XMLSchema#string

Mathilde Poussin

http://www.w3.org/2001/XMLSchema#string

Qunrui Ye

http://www.w3.org/2001/XMLSchema#string

Tori Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive immunotherapy for cancer: building on success

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

cDNA sequences of two inducible T-cell genes

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P304

44-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0945

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24045181

http://www.w3.org/2001/XMLSchema#string

P932

3947326

http://www.w3.org/2001/XMLSchema#string